News & Updates

Show Multimedia Only

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026 by

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

13 Aug 2026 by

Neoadjuvant immune checkpoint inhibitor (ICI) therapy demonstrates notable activity in non-metastatic deficient mismatch repair/microsatellite instability-high (dMMR/MSI) colorectal cancer (CRC), with high response rates and favourable clinical outcomes, as shown in the ongoing ambispective international observational study AGEO-NEO-MSI.

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

13 Aug 2026

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

12 Aug 2026

In patients with familial adenomatous polyposis (FAP), treatment with encapsulated rapamycin is safe and appears to lower polyp burden, according to a phase II study.

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

12 Aug 2026

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

12 Aug 2026 by

Treatment with STRIDE*, with or without lenvatinib, plus TACE** significantly improves progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) in patients with embolization-eligible hepatocellular carcinoma (eeHCC) compared with TACE alone, according to the phase III EMERALD-3 trial presented at ESMO GI 2026.

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

12 Aug 2026

Add-on high-dose vitamin D3 of little benefit in mCRC

11 Aug 2026

Adding high-dose vitamin D3 to standard chemotherapy does not appear to improve outcomes in patients with previously untreated metastatic colorectal cancer (mCRC), as shown in a phase III trial.

Add-on high-dose vitamin D3 of little benefit in mCRC

11 Aug 2026

Physical activity may ease symptoms, improve life quality in patients with celiac disease

10 Aug 2026

Engaging in physical activities (PAs) may ease inflammation and improve quality of life in patients with celiac disease (CD), an immune-mediated disorder triggered by gluten ingestion, suggests a study.

Physical activity may ease symptoms, improve life quality in patients with celiac disease

10 Aug 2026

8-strain probiotic formulation promising for bile acid malabsorption

09 Aug 2026

The De Simone formulation 8-strain probiotic appears to induce favourable microbiome and metabolome changes in patients with bile acid malabsorption, as shown in a study.

8-strain probiotic formulation promising for bile acid malabsorption

09 Aug 2026

Rice, refined carbohydrates raise risk of liver disease

08 Aug 2026

Higher intakes of total refined carbohydrate and rice appear to increase the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), but consumption of wheat, coarse grains, and yams may mitigate such threat, suggests a study.

Rice, refined carbohydrates raise risk of liver disease

08 Aug 2026

Simvastatin extends survival in patients with cirrhosis after variceal bleed

07 Aug 2026

Treatment with simvastatin appears to improve survival in some patients with cirrhosis after variceal bleed, suggests a study. The drug also reduces the incidence of new-onset, refractory ascites and its complications.

Simvastatin extends survival in patients with cirrhosis after variceal bleed

07 Aug 2026

Oral PPI mitigates delayed bleeding in G-ESD, G-EMR

07 Aug 2026 by

Oral administration of proton-pump inhibitor (PPI) helps reduce the risk of delayed bleeding in gastric endoscopic mucosal resection (G-EMR) and gastric endoscopic submucosal dissection (G-ESD) but not in esophageal endoscopic mucosal resection (E-EMR), esophageal endoscopic submucosal dissection (E-ESD), and percutaneous endoscopic gastrostomy (PEG), according to a study.

Oral PPI mitigates delayed bleeding in G-ESD, G-EMR

07 Aug 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

Add-on high-dose vitamin D3 of little benefit in mCRC

Add-on high-dose vitamin D3 of little benefit in mCRC

Physical activity may ease symptoms, improve life quality in patients with celiac disease

Physical activity may ease symptoms, improve life quality in patients with celiac disease

8-strain probiotic formulation promising for bile acid malabsorption

8-strain probiotic formulation promising for bile acid malabsorption

Rice, refined carbohydrates raise risk of liver disease

Rice, refined carbohydrates raise risk of liver disease

Simvastatin extends survival in patients with cirrhosis after variceal bleed

Simvastatin extends survival in patients with cirrhosis after variceal bleed

Oral PPI mitigates delayed bleeding in G-ESD, G-EMR

Oral PPI mitigates delayed bleeding in G-ESD, G-EMR